Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies-implications for solid tumors and potential for therapeutic inhibition

Growth Factors

Volumn 32, Issue 6, 2014, Pages 202-206

  Ferguson, Benjamin D ^a   Tretiakova, Maria S ^b   Lingen, Mark W ^c   Gill, Parkash S ^d   Salgia, Ravi ^a,e  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

EphB4; Head and neck cancer; Receptor tyrosine kinase; Renal cell carcinoma

Indexed keywords

EPHRIN RECEPTOR B4;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; ONCOCYTOMA; PROTEIN EXPRESSION; SOLID TUMOR; GENETICS; HEAD AND NECK TUMOR; KIDNEY TUMOR; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; RECEPTOR, EPHB4;

EID: 84918773471     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2014.980904     Document Type: Article

References (43)

1. Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, et al. 2006. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12:353-360
2. Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. 2007. Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers. Ann Oncol 18:485-490
3. Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. 2008. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br J Cancer 98:845-851
4. Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. 2009. Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers. Gynecol Oncol 114:84-88
5. Batlle E, Bacani J, Beghtel H, Jonkheer S, Jonkeer S, Gregorieff A, van De Born M, et al. 2005. EphB receptor activity suppresses colorectal cancer progression. Nature 435:1126-1130
6. Berclaz G, Karamitopoulou E, Mazzucchelli L, Rohrbach V, Dreher E, Ziemiecki A, Andres A-C. 2003. Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 14:220-226
7. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411:355-365
8. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. 2012. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 30:3287-3296
9. Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, Chen J. 2011. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS ONE 6:e24426
10. Chetcuti A, Aktas S, Mackie N, Ulger C, Toruner G, Alkan M, Catchpoole D. 2011. Expression profiling reveals MSX1 and EphB2 expression correlates with the invasion capacity of Wilms tumors. Pediatr Blood Cancer 57:950-957
11. Choong NW, Cohen EEW. 2006. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol 57: 25-43
12. Cohen EEW, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. 2003. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987
13. Cooper JB, Cohen EEW. 2009. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck 31:1086-1094
14. Ferguson BD, Liu R, Rolle CE, Tan Y-HC, Krasnoperov V, Kanteti R, Tretiakova MS, et al. 2013. The EphB4 receptor tyrosine kinase promotes lung cancer growth: A potential novel therapeutic target. PLoS ONE 8:e67668
15. Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, García JM, Salas C, Provencio M, Álvarez-Vallina L, Sanz L. 2013. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol 30: 572-579
16. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, et al. 2004. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50:490-499
17. Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, et al. 2013. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res 73:184-194
18. Kullander K, Klein R. 2002. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475-486
19. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, et al. 2007. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 96:1083-1091
20. Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, Manchanda PK, et al. 2009. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 69:3736-3745
21. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, et al. 2006. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 169:279-293
22. Lee Y-C, Perren JR, Douglas EL, Raynor MP, Bartley MA, Bardy PG, Stephenson S-A. 2005. Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma. BMC Cancer 5: 119-129
23. Li G, Ji X-D, Gao H, Zhao J-S, Xu J-F, Sun Z-J, Deng Y-Z, et al. 2012. EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/ RACK1/Akt signalling complex. Nat Commun 3:667-676
24. Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. 2013. EphB4 as a therapeutic target in mesothelioma. BMC Cancer 13:269-275
25. Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, et al. 2006. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer 119: 1236-1248
26. Ozgür E, Heidenreich A, Dagtekin O, Engelmann U, Bloch W. 2011. Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue. Urol Oncol 29:78-84
27. Price KAR, Cohen EE. 2012. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13:35-46
28. Roskoski R. 2013. The ErbB/HER family of protein-Tyrosine kinases and cancer. Pharmacol Res 79C:34-74
29. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, Dinali el M, Yala S, et al. 2009. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021-3031
30. Sharma GK, Dhillon VK, Masood R, Maceri DR. 2014. Overexpression of EphB4, EphrinB2 and EGFR in papillary thyroid carcinoma: A pilot study. Head Neck. [Epub ahead of print
31. Sinha UK, Kundra A, Scalia P, Smith DL, Parsa B, Masood R, Gill PS. 2003. Expression of EphB4 in head and neck squamous cell carcinoma. Ear Nose Throat J 82:866-887
32. Sinha UK, Mazhar K, Chinn SB, Dhillon VK, Liu L, Masood R, Rice DH, Gill PS. 2006. The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132:1053-1059
33. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MMK, Lee S-J, et al. 2010. Converging evidence for efficacy from parallel EphB4-Targeted approaches in ovarian carcinoma. Mol Cancer Ther 9:2377-2388
34. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. 2001. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2:15-23
35. Steube KG, Meyer C, Habig S, Uphoff CC, Drexler HG. 1999. Expression of receptor tyrosine kinase HTK (hepatoma transmembrane kinase) and HTK ligand by human leukemia-lymphoma cell lines. Leuk Lymphoma 33:371-376
36. Wagh PK, Peace BE, Waltz SE. 2008. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100: 1-33
37. Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, Mitra S, et al. 2013. Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res 19:128-137
38. Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM. 2006. The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol 102:15-21
39. Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. 2004. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 10:26-33
40. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, et al. 2005. EphB4 expression and biological significance in prostate cancer. Cancer Res 65:4623-4632
41. Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, et al. 2006. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 25: 769-780
42. Yang N-Y, Pasquale EB, Owen LB, Ethell IM. 2006. The EphB4 receptor-Tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. J Biol Chem 281:32574-32586
43. Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill PS, Masood R. 2008. The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 134:985-991